Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 23, 2025 07:00 ET | Source: Transpire Bio

Transpire Bio’s ANDA for Generic Breo® Ellipta® Accepted for Filing By the U.S. FDA

Transpire Bio's abbreviated new drug application for fluticasone furoate and vilanterol inhalation powder has been accepted for filing by the FDA
September 11, 2025 14:20 ET | Source: Custom Market Insights

[Latest] Global Pharmaceutical Metal Detector Market Size/Share Worth USD 270.93 Billion by 2034 at a 5.28% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Pharmaceutical Metal Detector Market Size, Trends and Insights By Technology...
September 07, 2025 20:30 ET | Source: InnoCare Pharma

InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Marginal Zone Lymphoma in Singapore

InnoCare's HIBRUKA (orelabrutinib) has been approved by the Health Sciences Authority (HSA) of Singapore for the treatment of adult patients with R/R MZL.
September 04, 2025 16:05 ET | Source: Lifecore Biomedical, Inc.

Lifecore Biomedical to Participate at 24th Annual Contract Pharma Contracting and Outsourcing Conference

CHASKA, Minn., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today...
September 04, 2025 08:30 ET | Source: Oncotelic Therapeutics, Inc.

Dr. Vuong Trieu, Developer of Novel Oncology and Immunotherapy Assets, Leads Oncotelic Therapeutics’ Commitment to Innovation, Life-Saving Therapies

Dr. Trieu’s prolific career includes multibillion-dollar drug discoveries targeting cancers of the breast, pancreas and non-small cell lung cancer, among others Oncotelic’s robust portfolio and...
September 03, 2025 16:30 ET | Source: Cellectis Inc.

Monthly information on share capital and company voting rights

PARIS, Sept. 03, 2025 (GLOBE NEWSWIRE) -- (Article 223-16 of General Regulation of the French financial markets authority) Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal...
September 02, 2025 09:00 ET | Source: Grand River Aseptic Manufacturing

Grand River Aseptic Manufacturing (GRAM) Appoints Denis Johnson as Chief Executive Officer

Grand Rapids, Michigan, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Grand River Aseptic Manufacturing (“GRAM” or the “Company”), a portfolio company of Arlington Capital Partners, today announced the...
August 28, 2025 08:00 ET | Source: Psyence Biomedical Ltd.

Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...
August 21, 2025 09:24 ET | Source: InnoCare Pharma

InnoCare Announces First Patient Dosed in the Registrational Trial of BCL2 Inhibitor Mesutoclax for Treatment of BTKi-treated MCL Patients in China

The first patient has been dosed in the registrational trial of InnoCare's BCL2 inhibitor mesutoclax for patients with BTK inhibitor treated MCL in China.
August 14, 2025 07:00 ET | Source: EvolveImmune

EvolveImmune Therapeutics Announces FDA Clearance of Investigational New Drug Application for EVOLVE104, a Novel Trispecific T Cell Engager with Integrated CD2 Costimulation

First Program from EVOLVE T-Cell Engager Platform to Advance into Clinical Development Phase 1 Clinical Trial of EVOLVE104 to be Initiated in 2025 BRANFORD, Conn., Aug. 14, 2025 (GLOBE NEWSWIRE)...